MA38523A1 - Composés triazoliques tricycliques utilisés en tant que ligands des récepteurs sigma - Google Patents
Composés triazoliques tricycliques utilisés en tant que ligands des récepteurs sigmaInfo
- Publication number
- MA38523A1 MA38523A1 MA38523A MA38523A MA38523A1 MA 38523 A1 MA38523 A1 MA 38523A1 MA 38523 A MA38523 A MA 38523A MA 38523 A MA38523 A MA 38523A MA 38523 A1 MA38523 A1 MA 38523A1
- Authority
- MA
- Morocco
- Prior art keywords
- ligands
- triazole compounds
- compounds used
- sigma receptors
- tricyclic triazole
- Prior art date
Links
- 108010085082 sigma receptors Proteins 0.000 title abstract 2
- -1 triazole compounds Chemical class 0.000 title abstract 2
- 239000003446 ligand Substances 0.000 title 1
- 102100028656 Sigma non-opioid intracellular receptor 1 Human genes 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108010080097 sigma-1 receptor Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La présente invention concerne de nouveaux composés triazoliques tricycliques de formule (i) présentant une grande affinité pour les récepteurs sigma, en particulier les récepteurs sigma-1, ainsi que le processus pour leur préparation, des compositions les comprenant et leur utilisation comme médicaments pour le traitement par exemple de maladies liées à la douleur.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13382143.9A EP2792679A1 (fr) | 2013-04-19 | 2013-04-19 | Composants triazoliques tricycliques |
| PCT/EP2014/058036 WO2014170494A1 (fr) | 2013-04-19 | 2014-04-21 | Composés triazoliques tricycliques utilisés en tant que ligands des récepteurs sigma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA38523A1 true MA38523A1 (fr) | 2017-03-31 |
Family
ID=48190443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38523A MA38523A1 (fr) | 2013-04-19 | 2014-04-21 | Composés triazoliques tricycliques utilisés en tant que ligands des récepteurs sigma |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US9512142B2 (fr) |
| EP (2) | EP2792679A1 (fr) |
| JP (1) | JP6337092B2 (fr) |
| KR (1) | KR102242405B1 (fr) |
| CN (1) | CN106029671B (fr) |
| AR (1) | AR095868A1 (fr) |
| AU (1) | AU2014255679B2 (fr) |
| BR (1) | BR112015026514B1 (fr) |
| CA (1) | CA2909735C (fr) |
| CY (1) | CY1119712T1 (fr) |
| DK (1) | DK2986616T3 (fr) |
| ES (1) | ES2628818T3 (fr) |
| HR (1) | HRP20170949T1 (fr) |
| HU (1) | HUE034797T2 (fr) |
| IL (1) | IL242096B (fr) |
| LT (1) | LT2986616T (fr) |
| MA (1) | MA38523A1 (fr) |
| MX (1) | MX362403B (fr) |
| MY (1) | MY194093A (fr) |
| PH (1) | PH12015502407B1 (fr) |
| PL (1) | PL2986616T3 (fr) |
| PT (1) | PT2986616T (fr) |
| RS (1) | RS56114B1 (fr) |
| RU (1) | RU2666728C2 (fr) |
| SG (1) | SG11201508610QA (fr) |
| SI (1) | SI2986616T1 (fr) |
| SM (1) | SMT201700315T1 (fr) |
| TN (1) | TN2015000470A1 (fr) |
| TW (1) | TWI601733B (fr) |
| UA (1) | UA116015C2 (fr) |
| WO (1) | WO2014170494A1 (fr) |
| ZA (1) | ZA201507775B (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024105225A1 (fr) | 2022-11-18 | 2024-05-23 | Universitat De Barcelona | Combinaisons synergiques d'un antagoniste du récepteur sigma 1 (s1r) et d'un inhibiteur d'époxyde hydrolase soluble (sehi) et leur utilisation dans le traitement de la douleur |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20000064893A (ko) * | 1996-07-20 | 2000-11-06 | 클래스 하인츠-게르트 | 트리아졸로퓨린,이의제조방법및이를함유하는약제학적제제 |
| AU2003245380A1 (en) * | 2002-05-30 | 2003-12-19 | King Pharmaceuticals Research & Development, Inc. | Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use |
| EP1634873A1 (fr) | 2004-08-27 | 2006-03-15 | Laboratorios Del Dr. Esteve, S.A. | Inhibiteurs des récepteurs sigma |
| PE20060653A1 (es) * | 2004-08-31 | 2006-09-27 | Glaxo Group Ltd | Derivados triciclicos condensados como moduladores del receptor 5-ht1 |
| EP1829869A1 (fr) | 2006-03-02 | 2007-09-05 | Laboratorios Del Dr. Esteve, S.A. | Dérivés de 4,5,6,7-tétrahydrobenzo[b]thiophène et leur utilisaton comme ligands du récepteur sigma |
| EP1847542A1 (fr) | 2006-04-21 | 2007-10-24 | Laboratorios del Dr. Esteve S.A. | Dérivés de spiro[benzopyran] ou de spiro[benzofuran] comme antagonistes du récepteur sigma |
| EP1849772A1 (fr) * | 2006-04-28 | 2007-10-31 | Laboratorios Del Dr. Esteve, S.A. | Dérivés bicyclic de Tetrahydopyrrole |
| EP1921071A1 (fr) * | 2006-11-10 | 2008-05-14 | Laboratorios del Dr. Esteve S.A. | 1,2,3-Triazoles en tant qu'inhibiteurs du récepteur sigma |
| EP2070933A1 (fr) * | 2007-12-07 | 2009-06-17 | Laboratorios del Dr. Esteve S.A. | Composants triazoliques tricycliques |
| US20110201599A1 (en) | 2008-07-03 | 2011-08-18 | Exelixis, Inc. | CDK Modulators |
-
2013
- 2013-04-19 EP EP13382143.9A patent/EP2792679A1/fr not_active Withdrawn
-
2014
- 2014-04-15 AR ARP140101605A patent/AR095868A1/es not_active Application Discontinuation
- 2014-04-18 TW TW103114141A patent/TWI601733B/zh active
- 2014-04-21 MA MA38523A patent/MA38523A1/fr unknown
- 2014-04-21 HR HRP20170949TT patent/HRP20170949T1/hr unknown
- 2014-04-21 MY MYPI2015002573A patent/MY194093A/en unknown
- 2014-04-21 PT PT147205389T patent/PT2986616T/pt unknown
- 2014-04-21 AU AU2014255679A patent/AU2014255679B2/en active Active
- 2014-04-21 WO PCT/EP2014/058036 patent/WO2014170494A1/fr not_active Ceased
- 2014-04-21 RU RU2015144720A patent/RU2666728C2/ru active
- 2014-04-21 UA UAA201510247A patent/UA116015C2/uk unknown
- 2014-04-21 JP JP2016508189A patent/JP6337092B2/ja active Active
- 2014-04-21 BR BR112015026514-6A patent/BR112015026514B1/pt active IP Right Grant
- 2014-04-21 ES ES14720538.9T patent/ES2628818T3/es active Active
- 2014-04-21 SG SG11201508610QA patent/SG11201508610QA/en unknown
- 2014-04-21 LT LTEP14720538.9T patent/LT2986616T/lt unknown
- 2014-04-21 CA CA2909735A patent/CA2909735C/fr active Active
- 2014-04-21 RS RS20170637A patent/RS56114B1/sr unknown
- 2014-04-21 PL PL14720538T patent/PL2986616T3/pl unknown
- 2014-04-21 HU HUE14720538A patent/HUE034797T2/en unknown
- 2014-04-21 EP EP14720538.9A patent/EP2986616B1/fr active Active
- 2014-04-21 TN TN2015000470A patent/TN2015000470A1/en unknown
- 2014-04-21 CN CN201480031192.0A patent/CN106029671B/zh active Active
- 2014-04-21 SM SM20170315T patent/SMT201700315T1/it unknown
- 2014-04-21 SI SI201430253T patent/SI2986616T1/sl unknown
- 2014-04-21 KR KR1020157032376A patent/KR102242405B1/ko active Active
- 2014-04-21 US US14/785,128 patent/US9512142B2/en active Active
- 2014-04-21 DK DK14720538.9T patent/DK2986616T3/da active
- 2014-04-21 MX MX2015014516A patent/MX362403B/es active IP Right Grant
-
2015
- 2015-10-15 IL IL242096A patent/IL242096B/en active IP Right Grant
- 2015-10-16 ZA ZA2015/07775A patent/ZA201507775B/en unknown
- 2015-10-16 PH PH12015502407A patent/PH12015502407B1/en unknown
-
2017
- 2017-06-20 CY CY20171100641T patent/CY1119712T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43409B1 (fr) | Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton | |
| MA41562B1 (fr) | Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires | |
| MA39783A (fr) | Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase | |
| MA40111B1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| MA39193B1 (fr) | Modulateurs du gpr6 à base de tétrahydropyridopyrazines | |
| MA35444B1 (fr) | Ligands du récepteur ep1 | |
| MA39219B1 (fr) | Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique | |
| MA39211B1 (fr) | Composés tricycliques comme agents anti-cancers | |
| MA47356A1 (fr) | Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases | |
| MA38284B1 (fr) | Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one | |
| MA39170A1 (fr) | Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer | |
| MA39145B1 (fr) | Dérivés de pipérazine ayant une activité multimode contre la douleur | |
| MA40875A (fr) | 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux | |
| MA38925B1 (fr) | Dérivés de phénylalanine substitués | |
| MA39337B1 (fr) | Modulateurs de pyrazines de gpr6 | |
| MX2015008733A (es) | Derivados de 1,2,3-triazol-4-amina para el tratamiento de enfermedades y transtornos relacionados con receptores sigma. | |
| MA39190A1 (fr) | Dérivés d'imidazolyle fusionnés, leur préparation et leur utilisation en tant que médicaments | |
| MA42988B1 (fr) | Dérivés d'éther spirocycliques de pyrazolo [1,5-a] pyrimidine-3-carboxamide | |
| MA43250B1 (fr) | Composés d'oxadiazaspiro pour le traitement de l'abus et la dépendance aux drogues | |
| MA38523A1 (fr) | Composés triazoliques tricycliques utilisés en tant que ligands des récepteurs sigma | |
| MA39750B1 (fr) | Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2 | |
| FR3029910B1 (fr) | Nouveaux composes 1-phenyl mono ou polyhydroxypropane, compositions et utilisation en cosmetique | |
| MA42871B1 (fr) | Composés utilisés comme inhibiteurs de la tyrosine kinase de bruton (btk) | |
| MA39260A1 (fr) | (benzyl-cyano-méthyl)-amides substitués de l'acide 2-aza-bicyclo[2.2.1]heptane-3-carboxylique utilisés comme inhibiteurs de la cathépsine c | |
| MA35894B1 (fr) | Composés d'oxazolidine-2-one et utilisations de ceux-ci en tant qu'inhibiteurs des pi3k |